Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20228502 | 1.00 | GAA (0.31) | GAAL3MBTL1POLBMEN1PKM | |
| SCHEMBL20228504 | 0.95 | ACHE (0.33) | MEN1PKMTSHRKMT2A | |
| SCHEMBL19968397 | 0.95 | ACHE (0.33) | MEN1PKMTSHRKMT2A | |
| SCHEMBL21150607 | 0.93 | ACHE (0.32) | MEN1PKMTSHRKMT2A | |
| SCHEMBL14045335 | 0.90 | MEN1 (0.33) | MEN1PKMTSHRKMT2A | |
| SCHEMBL14092707 | 0.90 | MEN1 (0.33) | MEN1PKMTSHRKMT2A | |
| SCHEMBL12084063 | 0.90 | MEN1 (0.33) | MEN1PKMTSHRKMT2A | |
| SCHEMBL12661273 | 0.90 | MEN1 (0.33) | MEN1PKMTSHRKMT2A | |
| SCHEMBL19968395 | 0.90 | MEN1 (0.33) | MEN1PKMTSHRKMT2A | |
| SCHEMBL2592750 | 0.90 | MEN1 (0.33) | MEN1PKMTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981156-B2 | Chromium complex and catalyst therefrom | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10919031-B2 | Process for oligomerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10376869-B2 | Process for oligomerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-10357764-B2 | Phosphacycle compound and process for production thereof | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190210013-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-10207262-B2 | Chromium complex and catalyst therefrom | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180154344-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180071725-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | GAA 3107/4885L3MBTL1 3427/4885POLB 886/4885 |
| US-20180071725-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | OXER1, LIG1, PICALM | GAA 3471/4885L3MBTL1 1859/4885POLB 1516/4885 |
| US-10919031-B2 | Process for oligomerization | OXER1, NOD1, LIG1 | GAA 3107/4885L3MBTL1 3427/4885POLB 886/4885 |
| US-10376869-B2 | Process for oligomerization | OXER1, NOD1, LIG1 | GAA 3107/4885L3MBTL1 3427/4885POLB 886/4885 |
| US-10981156-B2 | Chromium complex and catalyst therefrom | OXER1, LIG1, PICALM | GAA 3471/4885L3MBTL1 1859/4885POLB 1516/4885 |
| US-10357764-B2 | Phosphacycle compound and process for production thereof | OXER1, PPIP5K2, IP6K1 | GAA 3142/4885L3MBTL1 3870/4885POLB 780/4885 |
| US-10207262-B2 | Chromium complex and catalyst therefrom | OXER1, LIG1, PICALM | GAA 3471/4885L3MBTL1 1859/4885POLB 1516/4885 |
| US-20180154344-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | GAA 3107/4885L3MBTL1 3427/4885POLB 886/4885 |
| US-20190210013-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | OXER1, LIG1, PICALM | GAA 3471/4885L3MBTL1 1859/4885POLB 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.